A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study. Researchers hope these results, which were presented at the 2023 American Society of Clinical… Read More
Positive results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The trial assessed osimertinib as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor… Read More
DDW's Megan Thomas provides highlights from AACR 2023, the American Association of Cancer Research’s annual meeting from 14-19 April 2023 in Orlando, Florida, US. Meet the incoming AACR President Having said goodbye and thank you to Dr Lisa Coussens, AACR President for 2022-2023, Dr Philip Greenberg was inaugurated as President… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With National Cancer Research Month coming to an end in May and the American Society… Read More
News round-up for 29 May – 2 June by DDW Digital Content Editor Diana Spencer. With National Cancer Research Month coming to an end and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago (2-6 June), it’s been another… Read More
The latest eBook by DDW is out now. This 28-page eBook, sponsored by Benchling, examines the ways in which artificial intelligence and machine learning are expediting drug discovery efforts. Download this exclusive eBook to learn more about: The latest advancements in artificial intelligence… Read More
This latest eBook sponsored by Benchling features insight on how artificial intelligence is helping advance drug discovery efforts. Download this exclusive eBook to learn more about: The latest advancements in artificial intelligence How machine learning is being used across cancer research Why AI is critical to solving challenges in drug… Read More
Lifebit and Flatiron Health have announced a multi-year strategic partnership with the aim of improving scientific discoveries by learning from the experience of cancer patients. Health data generated by hospitals, healthcare providers, research organisations and clinical trials hold the potential to advance research and innovation, improve patient care and accelerate… Read More
Biopharmaceutical company Syros Pharmaceuticals has announced new clinical data from the Phase I/Ib clinical trial evaluating SY-5609 in patients with relapsed/refractory pancreatic ductal adenocarcinoma (PDAC), HR+ breast cancer and other solid tumours. The data will be presented in two posters at the 2023 American Society for… Read More
Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. The data indicate that AU-007 is well tolerated in patients with unresectable locally advanced or metastatic cancer and there are early signs of anti-tumour activity. Read More
From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. As the US National Cancer Research Month draws to a close, we asked experts from across the industry “What do… Read More
Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. With over 150 pharma services/supply companies and 19 universities, Scotland is one of the most advanced life science sectors in the UK and the world. To demonstrate how Scotland is… Read More
Pancreatic cancer cells can change their ‘diet’ to keep growing, by switching from the sugar glucose to a back-up fuel called uridine, new research has revealed. The findings suggest that blocking the availability of uridine using new drugs could become a new treatment strategy for the… Read More
Scientists in Japan have used a novel technique to identify a protein complex degraded by autophagy that has a possible role in liver cancer. Biomolecular condensates like p62 body have a role in cleansing cellular waste through ‘autophagy’, though much remains unknown about the constituents of… Read More
An ovarian cancer drug, which targets the alpha folate receptor (FRα), is set to enter Phase II trials. Idetrexed (formerly known as BTG945, ONX-0901 and CT900) was created by scientific teams in what is now The Institute of Cancer Research (ICR) Centre for Cancer Drug Discovery,… Read More
Jantzen Sperry, PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. The recent passage of the FDA Modernization Act, which removed the requirement for animal testing when suitable… Read More
